每经AI快讯，有投资者在投资者互动平台提问：请问贵公司黄岑苷胶囊、小儿双黄连颗粒，进展怎 样？在研中药和化药临床试验有哪些？ 太龙药业（600222.SH）8月20日在投资者互动平台表示，公司未研发或生产黄岑苷胶囊、小儿双黄连 颗粒。公司中药研发以经典名方、同名同方、已上市产品的二次开发和中药标准化研究等领域为主；子 公司新领先围绕临床价值明确、工艺技术壁高的改良型新药、高端复杂制剂开展受托研发和自主立项， 涵盖呼吸消化、感染、肿瘤、免疫、精神神经、心血管、眼科等领域的适应症，不断丰富在研项目储 备，拓展客户需求。 （文章来源：每日经济新闻） ...

格隆汇8月20日丨太龙药业(600222.SH)在投资者互动平台表示，公司未研发或生产黄岑苷胶囊，小儿双 黄连颗粒。公司中药研发以经典名方、同名同方、已上市产品的二次开发和中药标准化研究等领域为 主；子公司新领先围绕临床价值明确、工艺技术壁高的改良型新药、高端复杂制剂开展受托研发和自主 立项，涵盖呼吸消化、感染、肿瘤、免疫、精神神经、心血管、眼科等领域的适应症，不断丰富在研项 目储备，拓展客户需求。 ...

Group 1 - The company, Tailong Pharmaceutical (600222), announced the completion of its board of directors' re-election and the appointment of senior management and securities affairs representatives on August 15 [1] - The newly formed tenth board of directors includes Chairman Wang Rongtao, Vice Chairman Li Jingliang, and other members such as Chen Siliang, Chen Jinge, Luo Jianchao, Chen Qi (independent director with accounting expertise), Liu Yumin (independent director), Fang Liang (independent director), and Chen Fengyun (employee representative director) [1]

Meeting Overview - The third extraordinary general meeting of shareholders was held on August 15, 2025, at the company's conference room in Zhengzhou [2] - The meeting was convened by the board of directors and chaired by Chairman Yin Hui, using a combination of on-site and online voting [2][3] - All resolutions passed during the meeting were in compliance with the Company Law and the company's articles of association [2][5] Resolutions Passed - The proposal to abolish the supervisory board and amend the articles of association was approved [3] - Amendments to the rules of procedure for shareholder meetings, board meetings, and independent director work systems were also approved [4] - The election of the tenth board of directors, including both non-independent and independent directors, was conducted [4] Board of Directors Composition - The tenth board of directors consists of Chairman Wang Rongtao, Vice Chairman Li Jingliang, and other members including independent directors and a worker representative [30][31] - The board's term is set for three years, starting from the date of approval by the shareholders' meeting [31] Management Appointments - Li Jingliang was appointed as the General Manager, with other key appointments including Su Fengshan as Executive Vice General Manager and Zhao Hailin as Financial Officer [34] - The board secretary is Li Nianyun, and the securities affairs representative is Wu Ting, with all appointments aligned with the board's term [34][35] Legal Compliance - The meeting and its resolutions were witnessed by Henan Qianwen Law Firm, confirming that all procedures adhered to relevant laws and regulations [5][30]

Core Viewpoint - TaiLong Pharmaceutical's stock price increased by 3.24% to 7.00 CNY, reflecting positive market sentiment and trading activity [1] Company Overview - TaiLong Pharmaceutical operates in the pharmaceutical manufacturing industry, focusing on three core business segments: drug formulations, traditional Chinese medicine pieces, and pharmaceutical research and development services [1] - The company was established in 1993 and became the first listed pharmaceutical company in Henan Province when it went public on the Shanghai Stock Exchange in 1999 [1] Recent Developments - On August 15, TaiLong Pharmaceutical announced the completion of its board of directors' re-election and the appointment of senior management and securities affairs representatives [1] - The company elected five non-independent directors and three independent directors, with Wang Rongtao being appointed as the chairman of the tenth board of directors [1] - Wang Rongtao has previously held positions as the secretary and chairman of Zhengzhou High-tech Construction Group Co., Ltd., and currently serves as a member of the party branch and vice chairman of Zhengzhou High-tech Science City Investment Development Group Co., Ltd. [1] Stock Performance - The stock opened at 6.73 CNY, reached a high of 7.20 CNY, and a low of 6.64 CNY during the trading session [1] - The trading volume was 548,988 hands, with a total transaction value of 381 million CNY [1]

证券日报网讯 8月15日晚间，太龙药业发布公告称，公司2025年第三次临时股东大会审议通过了《关于 取消监事会并修订的议案》等多项议案。 （文章来源：证券日报） ...

Core Viewpoint - Tai Long Pharmaceutical announced the approval of multiple proposals, including the election of the chairman of the board at the first meeting of its tenth board of directors [2] Group 1 - The company held its first meeting of the tenth board of directors on August 15 [2] - The board approved the proposal for the election of the chairman [2]

Group 1 - The company announced that it will hold a staff representative meeting on August 15, 2025 [1] - Chen Fengyun has been democratically elected as the employee representative director of the company's tenth board of directors [1]

太龙药业（SH 600222，收盘价：7元）8月15日晚间发布公告称，公司第十届第一次董事会会议于2025 年8月15日在公司一楼会议室以现场结合通讯的方式召开。会议审议了《关于聘任公司董事会秘书的议 案》等文件。 2024年1至12月份，太龙药业的营业收入构成为：医药制造业占比79.38%，医药研发占比13.65%，医药 流通占比6.71%，其他业务占比0.27%。 （文章来源：每日经济新闻） ...

Core Points - The board of directors of Henan Tailong Pharmaceutical Co., Ltd. held its first meeting of the tenth session on August 15, 2025, with all nine directors present [1][2][3] - The meeting approved the election of Wang Rongtao as the chairman of the board, with a unanimous vote of 9 in favor [1] - Li Jingliang was elected as the vice chairman of the board, also with a unanimous vote of 9 in favor [2] - The board established various specialized committees, including the Strategy and Development Committee, Audit Committee, Nomination Committee, and Compensation and Assessment Committee, with all members elected unanimously [2] - Li Jingliang was appointed as the general manager of the company, with a unanimous vote of 9 in favor [3] - Su Fengshan was appointed as the executive vice general manager, and three others were appointed as vice general managers, all with unanimous approval [3] - Zhao Hailin was appointed as the financial officer, and Li Nianyun was appointed as the board secretary, both with unanimous votes [4] - Wu Ting was appointed as the securities affairs representative, also with unanimous approval [4]